Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A - BTXclintrialv1

Karolinska Institutet0 个研究点目标入组 40 人开始时间: 2024年6月10日最近更新: 2024年7月22日

试验速览

暂无简介。

•A diagnosis of myalgia or myofascial pain with referral according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) axix I, Female aged 20 – 45 years, A characteristic pain intensity of > 40/100, Pain upon digital palpation of at least one of the masseter muscles

•Difficulties understanding the Swedish language, Known allergy to botulinum toxin or antibiotics, Use of muscle relaxants, antidepressant, neuropsychiatric, or anticoagulant drugs, Use of analgesic or anti-inflammatory medication during the 48 hours preceding biopsy, Previous treatment with BTX during the last 12 months, Infection at the injection site, Systemic inflammatory connective tissue diseases (e.g. rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) c) widespread pain (e.g. fibromyalgia), Widespread pain (e.g. fibromyalgia), Neuromuscular disorders (e.g. craniomandibular dystonia, myasthenia gravis), Diagnosed or severe psychiatric disease (e.g. schizophrenia, bipolar disorder), Neuropathic pain, Pain of dental origin, History of trauma to the face, head or neck (incl. orthognathic surgery), Pregnancy or nursing

发起方